Clinical Trials Browser

Phase 1/2 × cabozantinib × Clear all

NCT06811116 2026-03-18

Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

Phase 1/2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT07293351 2026-03-04

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

Phase 1/2 Recruiting

Carcinoma, Renal Cell

NCT06716853 2026-02-09

TEM-GU

Phase 1/2 Terminated

Carcinoma, Renal Cell

NCT06835972 2026-01-15

A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)

Phase 1/2 Recruiting

Carcinoma, Renal Cell

NCT01658878 2025-12-24

CheckMate040

Phase 1/2 Completed

657 enrolled 57 charts 3 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT05039281 2025-12-19

Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma

Phase 1/2 Recruiting

Glioblastoma, Gliosarcoma

NCT05663710 2025-10-06

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

Phase 1/2 Recruiting

Carcinoma, Renal Cell

NCT03149822 2025-03-13

Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma

Phase 1/2 Completed

45 enrolled 17 charts

Carcinoma, Renal Cell

NCT03425201 2024-12-31

NICARAGUA

Phase 1/2 Completed

Urothelial Cancer

NCT05048901 2024-07-05

Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

Phase 1/2 Recruiting

Neuroendocrine Tumors

NCT04151563 2023-12-19

CheckMate 79X

Phase 1/2 Withdrawn

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT04300140 2023-10-30

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Phase 1/2 Terminated

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urologic Neoplasms

NCT03201250 2023-09-08

Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma

Phase 1/2 Terminated

11 enrolled 11 charts

Multiple Myeloma

NCT01683994 2019-11-08

Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer

Phase 1/2 Completed

49 enrolled 18 charts

Prostatic Neoplasms

NCT01866293 2017-08-30

Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma

Phase 1/2 Completed

11 enrolled 12 charts

Multiple Myeloma, Recurrence